ArticleCureus2025
Recurrent Optic Neuritis With MRI-Negative Myelopathy in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder that frequently presents with optic neuritis or myelitis, although early diagnostic evaluation may be challenging when neuroimaging is normal despite significant neurological deficits. We describe a 29-year-old woman who initially developed unilateral optic neuritis, followed one month later by sequential contralateral involvement and new sensory disturbances. She subsequently presented with acute bilateral lower-limb weakness, brisk reflexes, and lumbosacral sensory disturbance, although spinal MRI remained normal. Progressive neurological decline prompted treatment with high-dose IV corticosteroids and plasma exchange. MOG-IgG later returned positive, confirming MOGAD. The patient experienced gradual recovery of left-eye color perception and lower-limb strength, whereas right-eye visual acuity remained profoundly reduced. This case underscores the importance of recognizing recurrent or bilateral optic neuritis as a potential harbinger of MOGAD, appreciating that clinically evident myelopathy may occur with normal MRI, and initiating early neurology involvement and treatment escalation to prevent irreversible disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.